Nudge Communication for Flu Vaccination
(KP-VACCINATE Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to determine if special messages focused on heart health can encourage more people to get their flu shot. The study will compare these heart-focused messages, known as Cardiovascular-Focused Nudge Communication, with regular reminders to identify which is more effective at increasing flu vaccination rates. Participants will receive either the new cardiovascular-focused messages or standard messages at different times during the flu season. Eligible individuals are Kaiser Permanente members who haven't yet received a flu shot this season and have access to the KP HealthConnect® Portal or email. As an unphased trial, this study provides a unique opportunity to contribute to innovative research that could enhance public health strategies.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What prior data suggests that this communication strategy is safe for improving vaccination uptake?
Research shows that simple reminders about the heart health benefits of flu shots effectively encourage vaccination. Studies have found that people receive these reminders well, and they help increase vaccination rates. Importantly, no evidence suggests these reminders have negative effects. They are messages designed to promote healthy behavior by highlighting how flu vaccines protect heart health, making them very safe to use.12345
Why are researchers excited about this trial?
Researchers are excited about this trial because it explores an innovative approach to increasing flu vaccination rates using behavioral economics. The trial investigates cardiovascular-focused nudge communication, which is a fresh method compared to traditional reminders and educational campaigns. Unlike standard vaccination encouragement, which often relies on generic health messages, this approach tailors communication to highlight the cardiovascular benefits of getting vaccinated, potentially making it more relevant and motivating for certain individuals. By customizing messages to resonate with patients' health priorities, researchers hope to improve vaccination uptake and overall public health.
What evidence suggests that this trial's cardiovascular-focused nudge communication could be effective for increasing flu vaccination uptake?
Research has shown that messages focusing on heart health can effectively increase flu vaccination rates. In this trial, participants will receive different types of communication. Some will receive cardiovascular-focused nudge communication, which highlights how flu vaccines can benefit heart health, while others will receive usual care communication. Studies have found that heart-focused messages can increase vaccination rates by 11-14%. This method uses behavioral science to encourage vaccination by stressing the potential to prevent heart problems. Specifically, recipients of heart-focused messages were more likely to get their flu shots than those who received regular reminders. These findings suggest that emphasizing heart health benefits could be a promising way to boost flu vaccination rates.26789
Who Is on the Research Team?
Ankeet Bhatt, MD
Principal Investigator
The Permanente Medical Group
Benjamin Galper, MD
Principal Investigator
Mid-Atlantic Permanente Medical Group
Are You a Good Fit for This Trial?
This trial is for members of Kaiser Permanente in Northern California and the Mid Atlantic States who are eligible to receive an influenza vaccine. The study aims to see if special communication focused on heart health can increase flu shot rates.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Intervention
Participants receive either CV-focused nudge communication or usual care communication at two different timepoints during the influenza season
Follow-up
Participants are monitored for safety and effectiveness after intervention, including all-cause hospitalization, emergency department visits, and major adverse cardiovascular events
What Are the Treatments Tested in This Trial?
Interventions
- Cardiovascular-Focused Nudge Communication
Trial Overview
The trial is testing whether a cardiovascular-focused 'nudge' communication can boost influenza vaccination uptake compared to usual care messages during the flu season.
How Is the Trial Designed?
4
Treatment groups
Experimental Treatment
Active Control
Intervention arms will test the effects of a cardiovascular-focused nudge communication developed using behavioral economic principles. This arm will receive the usual care communication at first timepoint and then cardiovascular-focused nudge communication at the second timepoint during the influenza season.
Intervention arms will test the effects of a cardiovascular-focused nudge communication developed using behavioral economic principles. This arm will receive the cardiovascular-focused nudge communication at first timepoint and then usual care communication at the second timepoint during the influenza season.
Intervention arms will test the effects of a cardiovascular-focused nudge communication developed using behavioral economic principles. This arm will receive the cardiovascular-focused nudge communication at 2 different timepoints during the influenza season.
The usual care arm will receive standard-of-care communication encouraging vaccination at both timepoints during the influenza season.
Cardiovascular-Focused Nudge Communication is already approved in United States for the following indications:
- Improving influenza vaccination uptake among individuals with cardiovascular disease
Find a Clinic Near You
Who Is Running the Clinical Trial?
Kaiser Permanente
Lead Sponsor
Published Research Related to This Trial
Citations
Electronically delivered, cardiovascular-focused ...
First, this trial was specifically designed to evaluate the effectiveness and timing of a CV-focused nudge communication to promote influenza vaccination.
Study Details | NCT06571747 | Kaiser Permanente ...
KP VACCINATE is a multicenter, sequential, individual-level randomized controlled implementation trial examining the effectiveness of a CV-focused nudging ...
Prespecified Analysis of the NUDGE-FLU Trial | Circulation
Our results indicate that nudges focused on the cardiovascular benefits of influenza vaccines may be an effective strategy for inducing ...
Electronic Nudges to Increase Influenza Vaccination in ...
All 6 intervention strategies markedly increased influenza vaccination rates with absolute effect sizes ranging between 11-14 percentage points.
Electronic Nudges to Increase Influenza Vaccination in ...
Can electronically delivered letter-based nudges informed by behavioral science increase influenza vaccination uptake among young and ...
Cardiovascular-Focused Messaging to Improve Influenza ...
Cardiovascular-Focused Messaging to Improve Influenza Vaccination Rates.
7.
ahajournals.org
ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.064270?doi=10.1161/CIRCULATIONAHA.123.064270Effect of Electronic Nudges on Influenza Vaccination Rate ...
Our results indicate that nudges focused on the cardiovascular benefits of influenza vaccines may be an effective strategy for inducing behavioral change ...
8.
withpower.com
withpower.com/trial/phase-social-behavior-8-2024-0a3b4?condition=influenza&hasNoPlacebo=false&overallStatus=RecruitingNudge Communication for Flu Vaccination
In randomized clinical trials and observational studies, influenza vaccination is effective in reducing influenza-related illness and hospitalizations and ...
Influence of Digital Intervention Messaging on Influenza ...
Electronic nudges increase influenza vaccination utilization after myocardial infarction: the nationwide NUDGE-FLU implementation trial.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.